Post-earnings recap
Reported
Tue, May 10, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Viking Therapeutics reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising 7.63%. The company is making progress in its clinical trials, which investors seem to view favorably. However, the lack of revenue data and future guidance leaves some uncertainty about the company's financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | +11.11% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a positive outlook on their clinical developments. However, they did not provide specific guidance for the future.
Management highlighted ongoing progress in clinical trials.
They emphasized a commitment to advancing their pipeline.
No specific guidance was provided for future quarters.